Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 518

1.

The impact of re-induction prior to salvage autologous stem cell transplantation in multiple myeloma.

Miller KC, Gertz MA, Buadi FK, Hayman SR, Lacy MQ, Dispenzieri AA, Dingli D, Kapoor P, Gonsalves WI, Kourelis T, Muchtar E, Hogan WJ, Kumar SK.

Bone Marrow Transplant. 2019 Jun 12. doi: 10.1038/s41409-019-0590-5. [Epub ahead of print]

PMID:
31190005
2.

Development of thrombocytopenia during first-line treatment and survival outcomes in newly diagnosed multiple myeloma.

Mellors PW, Binder M, Buadi FK, Lacy MQ, Gertz MA, Dispenzieri A, Hayman SR, Kapoor P, Gonsalves WI, Hwa YL, Fonder A, Hobbs M, Kourelis T, Warsame R, Zeldenrust SR, Lust JA, Leung N, Go RS, Kyle RA, Rajkumar SV, Kumar SK.

Leuk Lymphoma. 2019 May 16:1-8. doi: 10.1080/10428194.2019.1613536. [Epub ahead of print]

PMID:
31096812
3.

The first-in-human study of the pan-PIM kinase inhibitor PIM447 in patients with relapsed and/or refractory multiple myeloma.

Raab MS, Thomas SK, Ocio EM, Guenther A, Goh YT, Talpaz M, Hohmann N, Zhao S, Xiang F, Simon C, Vanasse KG, Kumar SK.

Leukemia. 2019 May 15. doi: 10.1038/s41375-019-0482-0. [Epub ahead of print]

PMID:
31092894
4.

Recycling therapies for myeloma: The need for prospective trials.

Kumar SK.

Cancer. 2019 May 15. doi: 10.1002/cncr.32177. [Epub ahead of print] No abstract available.

PMID:
31090923
5.

Outcomes of Patients with Light Chain Amyloidosis Who Had Autologous Stem Cell Transplantation with 3 or More Organs Involved.

Al Saleh AS, Sidiqi MH, Muchtar E, Dispenzieri A, Buadi FK, Dingli D, Lacy MQ, Warsame RM, Gonsalves WI, Kourelis TV, Hogan WJ, Hayman SR, Kapoor P, Kumar SK, Gertz MA.

Biol Blood Marrow Transplant. 2019 May 2. pii: S1083-8791(19)30271-X. doi: 10.1016/j.bbmt.2019.04.024. [Epub ahead of print]

PMID:
31054986
6.

Comparison of different techniques to identify cardiac involvement in immunoglobulin light chain (AL) amyloidosis.

Aljama MA, Sidiqi MH, Dispenzieri A, Gertz MA, Lacy MQ, Buadi FK, Dingli D, Muchtar E, Fonder AL, Hayman SR, Hobbs MA, Gonsalves WI, Warsame RM, Kourelis T, Hwa YL, Kapoor P, Leung N, Go RS, Kyle RA, Rajkumar SV, Kumar SK.

Blood Adv. 2019 Apr 23;3(8):1226-1229. doi: 10.1182/bloodadvances.2019032458.

7.

Autologous stem cell transplantation in patients with AL amyloidosis with impaired renal function.

Sidiqi MH, Nadiminti K, Al Saleh AS, Meleveedu K, Buadi FK, Dispenzieri A, Warsame R, Lacy MQ, Dingli D, Leung N, Gonsalves WI, Kapoor P, Kourelis TV, Hogan WJ, Kumar SK, Gertz MA.

Bone Marrow Transplant. 2019 Apr 8. doi: 10.1038/s41409-019-0524-2. [Epub ahead of print]

PMID:
30962503
8.

Prognostic value of minimal residual disease and polyclonal plasma cells in myeloma patients achieving a complete response to therapy.

Tschautscher MA, Jevremovic D, Rajkumar V, Dispenzieri A, Lacy MQ, Gertz MA, Buadi FK, Dingli D, Hwa YL, Fonder AL, Hobbs MA, Hayman SR, Zeldenrust SR, Lust JA, Russell SJ, Leung N, Kapoor P, Go RS, Lin Y, Gonsalves WI, Kourelis T, Warsame R, Kyle RA, Kumar SK.

Am J Hematol. 2019 Jul;94(7):751-756. doi: 10.1002/ajh.25481. Epub 2019 Apr 30.

PMID:
30945330
9.

Outcomes of patients with multiple myeloma refractory to CD38-targeted monoclonal antibody therapy.

Gandhi UH, Cornell RF, Lakshman A, Gahvari ZJ, McGehee E, Jagosky MH, Gupta R, Varnado W, Fiala MA, Chhabra S, Malek E, Mansour J, Paul B, Barnstead A, Kodali S, Neppalli A, Liedtke M, Narayana S, Godby KN, Kang Y, Kansagra A, Umyarova E, Scott EC, Hari P, Vij R, Usmani SZ, Callander NS, Kumar SK, Costa LJ.

Leukemia. 2019 Mar 11. doi: 10.1038/s41375-019-0435-7. [Epub ahead of print]

PMID:
30858549
10.

Natural history of multiple myeloma with de novo del(17p).

Lakshman A, Painuly U, Rajkumar SV, Ketterling RP, Kapoor P, Greipp PT, Gertz MA, Buadi FK, Lacy MQ, Dingli D, Dispenzieri A, Fonder AL, Hayman SR, Hobbs MA, Gonsalves WI, Hwa YL, Leung N, Go RS, Lin Y, Kourelis TV, Warsame R, Lust JA, Russell SJ, Zeldenrust SR, Kyle RA, Kumar SK.

Blood Cancer J. 2019 Mar 7;9(3):32. doi: 10.1038/s41408-019-0191-y.

11.

Histone deacetylase inhibition in combination with MEK or BCL-2 inhibition in multiple myeloma.

Ramakrishnan VG, Miller KC, Macon EP, Kimlinger TK, Haug J, Kumar S, Gonsalves WI, Rajkumar SV, Kumar SK.

Haematologica. 2019 Mar 7. pii: haematol.2018.211110. doi: 10.3324/haematol.2018.211110. [Epub ahead of print]

12.

Correction: Management of relapsed and refractory multiple myeloma: novel agents, antibodies, immunotherapies and beyond.

Chim CS, Kumar SK, Orlowski RZ, Cook G, Richardson PG, Gertz MA, Giralt S, Mateos MV, Leleu X, Anderson KC.

Leukemia. 2019 Apr;33(4):1058-1059. doi: 10.1038/s41375-019-0410-3.

PMID:
30842604
13.

Clinical features, laboratory characteristics and outcomes of patients with renal versus cardiac light chain amyloidosis.

Sidana S, Tandon N, Gertz MA, Dispenzieri A, Ramirez-Alvarado M, Murray DL, Kourelis TV, Buadi FK, Kapoor P, Gonsalves W, Warsame R, Lacy MQ, Kyle RA, Rajkumar SV, Kumar SK, Leung N.

Br J Haematol. 2019 May;185(4):701-707. doi: 10.1111/bjh.15832. Epub 2019 Mar 5.

PMID:
30836444
14.

Outcomes with early response to first-line treatment in patients with newly diagnosed multiple myeloma.

Tandon N, Sidana S, Rajkumar SV, Gertz MA, Buadi FK, Lacy MQ, Kapoor P, Gonsalves WI, Dispenzieri A, Kourelis TV, Warsame R, Dingli D, Fonder AL, Hayman SR, Hobbs MA, Hwa YL, Kyle RA, Leung N, Go RS, Lust JA, Russell SJ, Kumar SK.

Blood Adv. 2019 Mar 12;3(5):744-750. doi: 10.1182/bloodadvances.2018022806.

15.

Impact of prior diagnosis of monoclonal gammopathy on outcomes in newly diagnosed multiple myeloma.

Goyal G, Rajkumar SV, Lacy MQ, Gertz MA, Buadi FK, Dispenzieri A, Hwa YL, Fonder AL, Hobbs MA, Hayman SR, Zeldenrust SR, Lust JA, Russell SJ, Leung N, Kapoor P, Go RS, Gonsalves WI, Kourelis TV, Warsame R, Kyle RA, Kumar SK.

Leukemia. 2019 May;33(5):1273-1277. doi: 10.1038/s41375-019-0419-7. Epub 2019 Feb 20.

PMID:
30787429
16.

A Modern Primer on Light Chain Amyloidosis in 592 Patients With Mass Spectrometry-Verified Typing.

Muchtar E, Gertz MA, Kyle RA, Lacy MQ, Dingli D, Leung N, Buadi FK, Hayman SR, Kapoor P, Hwa YL, Fonder A, Hobbs M, Gonsalves W, Kourelis TV, Warsame R, Russell S, Lust JA, Lin Y, Go RS, Zeldenrust S, Rajkumar SV, Kumar SK, Dispenzieri A.

Mayo Clin Proc. 2019 Mar;94(3):472-483. doi: 10.1016/j.mayocp.2018.08.006. Epub 2019 Feb 13. Erratum in: Mayo Clin Proc. 2019 Jun;94(6):1121.

PMID:
30770096
17.

Substratification of patients with newly diagnosed standard-risk multiple myeloma.

Binder M, Rajkumar SV, Ketterling RP, Dispenzieri A, Lacy MQ, Gertz MA, Buadi FK, Hayman SR, Hwa YL, Zeldenrust SR, Lust JA, Russell SJ, Leung N, Kapoor P, Go RS, Gonsalves WI, Kyle RA, Kumar SK.

Br J Haematol. 2019 Apr;185(2):254-260. doi: 10.1111/bjh.15800. Epub 2019 Feb 15.

PMID:
30768679
18.

Prognostic restaging at the time of second-line therapy in patients with AL amyloidosis.

Hwa YL, Gertz MA, Kumar SK, Lacy MQ, Buadi FK, Dingli D, Kapoor P, Zeldenrust SR, Leung N, Hayman SR, Gonsalves WI, Kourelis TV, Warsame R, Go RS, Muchtar E, Hobbs MA, Fonder AL, Russell S, Kyle RA, Rajkumar SV, Dispenzieri A.

Leukemia. 2019 May;33(5):1268-1272. doi: 10.1038/s41375-019-0400-5. Epub 2019 Feb 8.

PMID:
30737485
19.

Prognostic Significance of Holter Monitor Findings in Patients With Light Chain Amyloidosis.

Sidana S, Tandon N, Brady PA, Grogan M, Gertz MA, Dispenzieri A, Lin G, Dingli D, Buadi FK, Lacy MQ, Kapoor P, Gonsalves WI, Muchtar E, Warsame R, Kumar SK, Kourelis TV.

Mayo Clin Proc. 2019 Mar;94(3):455-464. doi: 10.1016/j.mayocp.2018.08.039. Epub 2019 Feb 2.

PMID:
30718070
20.

The stepchild in myeloma treatments: is allogeneic transplantation not so bad after all?

Müller AMS, Kumar SK, Bruno B.

Haematologica. 2019 Feb;104(2):222-225. doi: 10.3324/haematol.2018.206987. No abstract available.

21.

Ixazomib, lenalidomide, and dexamethasone in patients with newly diagnosed multiple myeloma: long-term follow-up including ixazomib maintenance.

Kumar SK, Berdeja JG, Niesvizky R, Lonial S, Laubach JP, Hamadani M, Stewart AK, Hari P, Roy V, Vescio R, Kaufman JL, Berg D, Liao E, Rajkumar SV, Richardson PG.

Leukemia. 2019 Jan 29. doi: 10.1038/s41375-019-0384-1. [Epub ahead of print]

PMID:
30696949
22.

Targeted Management Strategies in Multiple Myeloma.

Kumar SK.

Cancer J. 2019 Jan/Feb;25(1):59-64. doi: 10.1097/PPO.0000000000000353.

PMID:
30694861
23.

Tetraploidy is associated with poor prognosis at diagnosis in multiple myeloma.

Sidana S, Jevremovic D, Ketterling RP, Tandon N, Greipp PT, Baughn LB, Dispenzieri A, Gertz MA, Rajkumar SV, Kumar SK.

Am J Hematol. 2019 May;94(5):E117-E120. doi: 10.1002/ajh.25420. Epub 2019 Feb 6. No abstract available.

PMID:
30680770
24.

Comparative analysis of staging systems in AL amyloidosis.

Muchtar E, Therneau TM, Larson DR, Gertz MA, Lacy MQ, Buadi FK, Dingli D, Hayman SR, Kapoor P, Gonsalves W, Kourelis TV, Warsame R, Fonder A, Hobbs M, Hwa YL, Leung N, Russell S, Lust JA, Lin Y, Go RS, Zeldenrust S, Kyle RA, Rajkumar SV, Kumar SK, Dispenzieri A.

Leukemia. 2019 Mar;33(3):811-814. doi: 10.1038/s41375-018-0370-z. Epub 2019 Jan 23. No abstract available.

PMID:
30675009
25.

Rapid assessment of hyperdiploidy in plasma cell disorders using a novel multi-parametric flow cytometry method.

Sidana S, Jevremovic D, Ketterling RP, Tandon N, Dispenzieri A, Gertz MA, Greipp PT, Baughn LB, Buadi FK, Lacy MQ, Morice W, Hanson C, Timm M, Dingli D, Hayman SR, Gonsalves WI, Kapoor P, Kyle RA, Leung N, Go RS, Lust JA, Rajkumar SV, Kumar SK.

Am J Hematol. 2019 Apr;94(4):424-430. doi: 10.1002/ajh.25391. Epub 2019 Jan 8.

PMID:
30592078
26.

Pros and cons of frontline autologous transplant in multiple myeloma: the debate over timing.

Kumar SK, Buadi FK, Rajkumar SV.

Blood. 2019 Feb 14;133(7):652-659. doi: 10.1182/blood-2018-08-825349. Epub 2018 Dec 26. Review.

PMID:
30587528
27.

Modeling gas transport in polymer-grafted nanoparticle membranes.

Barnett JW, Kumar SK.

Soft Matter. 2019 Jan 21;15(3):424-432. doi: 10.1039/c8sm02235f. Epub 2018 Dec 20.

PMID:
30569058
28.

Staging systems use for risk stratification of systemic amyloidosis in the era of high-sensitivity troponin T assay.

Muchtar E, Kumar SK, Gertz MA, Grogan M, AbouEzzeddine OF, Jaffe AS, Dispenzieri A.

Blood. 2019 Feb 14;133(7):763-766. doi: 10.1182/blood-2018-10-875252. Epub 2018 Dec 13. No abstract available.

PMID:
30545829
29.

Overall survival of transplant eligible patients with newly diagnosed multiple myeloma: comparative effectiveness analysis of modern induction regimens on outcome.

Paquin AR, Kumar SK, Buadi FK, Gertz MA, Lacy MQ, Dispenzieri A, Dingli D, Hwa L, Fonder A, Hobbs M, Hayman SR, Zeldenrust SR, Lust JA, Russell SJ, Leung N, Kapoor P, Go RS, Lin Y, Gonsalves WI, Kourelis T, Warsame R, Kyle RA, Rajkumar SV.

Blood Cancer J. 2018 Dec 11;8(12):125. doi: 10.1038/s41408-018-0163-7.

30.

Autologous Stem Cell Transplant for IgM-Associated Amyloid Light-Chain Amyloidosis.

Sidiqi MH, Buadi FK, Dispenzieri A, Warsame R, Lacy MQ, Dingli D, Leung N, Gonsalves WI, Kapoor P, Kourelis TV, Hogan WJ, Kumar SK, Gertz MA.

Biol Blood Marrow Transplant. 2019 Mar;25(3):e108-e111. doi: 10.1016/j.bbmt.2018.12.003. Epub 2018 Dec 7.

PMID:
30529461
31.

Peripheral blood biomarkers of early immune reconstitution in newly diagnosed multiple myeloma.

Binder M, Rajkumar SV, Lacy MQ, Gertz MA, Buadi FK, Dispenzieri A, Hwa YL, Fonder A, Hobbs M, Hayman SR, Zeldenrust SR, Lust JA, Russell SJ, Leung N, Kapoor P, Go RS, Gonsalves WI, Kourelis T, Warsame R, Kyle RA, Kumar SK.

Am J Hematol. 2019 Mar;94(3):306-311. doi: 10.1002/ajh.25365. Epub 2018 Dec 13.

PMID:
30516847
32.

Development of the Smartphone-Assisted Colorimetric Detection of Thorium by Using New Schiff's Base and Its Applications to Real Time Samples.

R SK, Kumar SKA, Vijayakrishna K, Sivaramakrishna A, Brahmmananda Rao CVS, Sivaraman N, Sahoo SK.

Inorg Chem. 2018 Dec 17;57(24):15270-15279. doi: 10.1021/acs.inorgchem.8b02564. Epub 2018 Dec 5.

PMID:
30516379
33.

Diminishing Interfacial Effects with Decreasing Nanoparticle Size in Polymer-Nanoparticle Composites.

Emamy H, Kumar SK, Starr FW.

Phys Rev Lett. 2018 Nov 16;121(20):207801. doi: 10.1103/PhysRevLett.121.207801.

PMID:
30500219
34.

Defining the optimal criterion for separating gases using polymeric membranes.

Zhang K, Kumar SK.

Soft Matter. 2018 Dec 12;14(48):9847-9850. doi: 10.1039/c8sm02012d.

PMID:
30489596
35.

Should we measure clonal circulating plasma cells in light chain amyloidosis?

Sidana S, Kumar SK, Gonsalves WI.

Oncotarget. 2018 Nov 2;9(86):35607-35608. doi: 10.18632/oncotarget.26289. eCollection 2018 Nov 2. No abstract available.

36.

Plasma cell proliferative index is an independent predictor of progression in smoldering multiple myeloma.

Aljama MA, Sidiqi MH, Lakshman A, Dispenzieri A, Jevremovic D, Gertz MA, Lacy MQ, Buadi FK, Dingli D, Muchtar E, Fonder AL, Hayman SR, Hobbs MA, Gonsalves WI, Warsame R, Kourelis TV, Hwa YL, Kapoor P, Leung N, Go RS, Kyle RA, Rajkumar SV, Kumar SK.

Blood Adv. 2018 Nov 27;2(22):3149-3154. doi: 10.1182/bloodadvances.2018024794.

37.

Phase 2 study of all-oral ixazomib, cyclophosphamide and low-dose dexamethasone for relapsed/refractory multiple myeloma.

Kumar SK, Grzasko N, Delimpasi S, Jedrzejczak WW, Grosicki S, Kyrtsonis MC, Spencer A, Gupta N, Teng Z, Byrne C, Labotka R, Dimopoulos MA.

Br J Haematol. 2019 Feb;184(4):536-546. doi: 10.1111/bjh.15679. Epub 2018 Nov 20.

PMID:
30460684
38.

Revised diagnostic criteria for plasma cell leukemia: results of a Mayo Clinic study with comparison of outcomes to multiple myeloma.

Ravi P, Kumar SK, Roeker L, Gonsalves W, Buadi F, Lacy MQ, Go RS, Dispenzieri A, Kapoor P, Lust JA, Dingli D, Lin Y, Russell SJ, Leung N, Gertz MA, Kyle RA, Bergsagel PL, Rajkumar SV.

Blood Cancer J. 2018 Nov 15;8(12):116. doi: 10.1038/s41408-018-0140-1.

39.

Validation of Mayo Clinic Staging System for Light Chain Amyloidosis With High-Sensitivity Troponin.

Kumar SK, Gertz MA, Dispenzieri A.

J Clin Oncol. 2019 Jan 10;37(2):171-173. doi: 10.1200/JCO.18.01398. Epub 2018 Nov 15. No abstract available.

PMID:
30433848
40.

Timing of treatment of smoldering myeloma: delay until progression.

Kumar SK.

Blood Adv. 2018 Nov 13;2(21):3050-3053. doi: 10.1182/bloodadvances.2018021238. No abstract available.

41.

Ixazomib for the treatment of multiple myeloma.

Richardson PG, Zweegman S, O'Donnell EK, Laubach JP, Raje N, Voorhees P, Ferrari RH, Skacel T, Kumar SK, Lonial S.

Expert Opin Pharmacother. 2018 Dec;19(17):1949-1968. doi: 10.1080/14656566.2018.1528229. Epub 2018 Nov 13. Review.

PMID:
30422008
42.

Interpreting clinical trial data in multiple myeloma: translating findings to the real-world setting.

Richardson PG, San Miguel JF, Moreau P, Hajek R, Dimopoulos MA, Laubach JP, Palumbo A, Luptakova K, Romanus D, Skacel T, Kumar SK, Anderson KC.

Blood Cancer J. 2018 Nov 9;8(11):109. doi: 10.1038/s41408-018-0141-0. Review.

43.

Bortezomib, lenalidomide, and dexamethasone (VRd) followed by autologous stem cell transplant for multiple myeloma.

Sidiqi MH, Aljama MA, Bin Riaz I, Dispenzieri A, Muchtar E, Buadi FK, Warsame R, Lacy MQ, Dingli D, Leung N, Gonsalves WI, Kapoor P, Kourelis TV, Hogan WJ, Rajkumar SV, Kumar SK, Gertz MA.

Blood Cancer J. 2018 Nov 8;8(11):106. doi: 10.1038/s41408-018-0147-7.

44.

Safety and efficacy of propylene glycol-free melphalan as conditioning in patients with AL amyloidosis undergoing stem cell transplantation.

Sidiqi MH, Aljama MA, Muchtar E, Buadi FK, Warsame R, Lacy MQ, Dispenzieri A, Dingli D, Leung N, Gonsalves WI, Kapoor P, Kourelis TV, Hogan WJ, Wolf RC, Kumar SK, Gertz MA.

Bone Marrow Transplant. 2018 Nov 2. doi: 10.1038/s41409-018-0388-x. [Epub ahead of print]

PMID:
30390060
45.

Bibliometric Analysis of the Top 100 Most Cited Articles in the First 50 Years of Heart Transplantation.

Kolkailah AA, Fugar S, Vondee N, Hirji SA, Okoh AK, Ayoub A, Al-Ogaili A, Paz Rios LH, Kumar SK, Camacho MT, Rich JD, Golzar Y.

Am J Cardiol. 2019 Jan 1;123(1):175-186. doi: 10.1016/j.amjcard.2018.09.010. Epub 2018 Sep 26.

PMID:
30385032
46.

Relapse after complete response in newly diagnosed multiple myeloma: implications of duration of response and patterns of relapse.

Sidana S, Tandon N, Dispenzieri A, Gertz MA, Buadi FK, Lacy MQ, Dingli D, Fonder AL, Hayman SR, Hobbs MA, Gonsalves WI, Warsame RM, Kourelis T, Hwa YL, Kapoor P, Kyle RA, Leung N, Go RS, Rajkumar SV, Kumar SK.

Leukemia. 2019 Mar;33(3):730-738. doi: 10.1038/s41375-018-0271-1. Epub 2018 Oct 15.

PMID:
30323358
47.

Surface Fluctuations Dominate the Slow Glassy Dynamics of Polymer-Grafted Colloid Assemblies.

Asai M, Cacciuto A, Kumar SK.

ACS Cent Sci. 2018 Sep 26;4(9):1179-1184. doi: 10.1021/acscentsci.8b00352. Epub 2018 Aug 27.

48.

Optimizing deep response assessment for AL amyloidosis using involved free light chain level at end of therapy: failure of the serum free light chain ratio.

Muchtar E, Dispenzieri A, Leung N, Lacy MQ, Buadi FK, Dingli D, Hayman SR, Kapoor P, Hwa YL, Fonder A, Hobbs M, Gonsalves W, Kourelis TV, Warsame R, Russell SJ, Lust JA, Lin Y, Go RS, Zeldenrust SR, Kyle RA, Rajkumar SV, Kumar SK, Gertz MA.

Leukemia. 2019 Feb;33(2):527-531. doi: 10.1038/s41375-018-0258-y. Epub 2018 Sep 26. No abstract available.

PMID:
30258095
49.

Synergy between tuberculin skin test and proliferative T cell responses to PPD or cell-membrane antigens of Mycobacterium tuberculosis for detection of latent TB infection in a high disease-burden setting.

Arya S, Kumar SK, Nath A, Kapoor P, Aggarwal A, Misra R, Sinha S.

PLoS One. 2018 Sep 24;13(9):e0204429. doi: 10.1371/journal.pone.0204429. eCollection 2018.

50.

Accurate estimation of the polymer coverage of hairy nanoparticles.

Asai M, Zhao D, Kumar SK.

Soft Matter. 2018 Oct 3;14(38):7906-7915. doi: 10.1039/c8sm01311j.

PMID:
30230511

Supplemental Content

Loading ...
Support Center